Calliditas Therapeutics AB (publ)

NASDAQ (USD): Calliditas Therapeutics AB (publ) (CALT)

Last Price

39.05

Today's Change

-0.19 (0.48%)

Day's Change

38.80 - 39.08

Trading Volume

3,214

Overview

Market Cap

1 Billion

Shares Outstanding

26 Million

Avg Volume

12,703

Avg Price (50 Days)

26.00

Avg Price (200 Days)

21.50

PE Ratio

-20.77

EPS

-1.88

Earnings Announcement

13-Aug-2024

Previous Close

39.24

Open

38.99

Day's Range

38.8 - 39.0816

Year Range

15.25 - 41.9

Trading Volume

3,214

Price Change Highlight

1 Day Change

-0.48%

5 Day Change

-0.48%

1 Month Change

75.98%

3 Month Change

77.10%

6 Month Change

73.56%

Ytd Change

56.20%

1 Year Change

114.56%

3 Year Change

39.22%

5 Year Change

99.23%

10 Year Change

99.23%

Max Change

99.23%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment